Check 35,000+ stocks against 26 valuation models and 37 quality factors

Lumos Diagnostics Holdings Limited (LDXHF) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Lumos Diagnostics Holdings Limited $0.03, price $0.07, upside -57.1%, quality 15 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · Home Australia

Thin data Jun 24, 2026

Lumos Diagnostics Holdings Limited

LDXHF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0300 · Strongly overvalued (−57.1%)

!Quality 15/100

!Weak Growth (revenue 5y −6.6 %/yr)

!Loss-making · -37.5% net margin (TTM)

!negative free cash flow

!Trails peers (1/9)

!Narrow moat 3/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.0200 to bull $0.0400 Growth analysisrevenue history, year by year Quality 15/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Lumos Diagnostics Holdings Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range $0.0066 – $0.8000 · fair‑value band $0.0200 – $0.0400 · the $0.0700 price screens above the $0.0300 fair value. Dashed = 300-day average. As of Jun 24, 2026.

Follow Lumos Diagnostics Holdings in your weekly email

Every Wednesday you see whether Lumos Diagnostics Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States.

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.

Stock analysis

Lumos Diagnostics Holdings Limited (LDXHF) currently trades at $0.0700, while our model-based Fair Value estimate is $0.0300, 57.1% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0200 (bear) to $0.0400 (bull), the price of $0.0700 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 15/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Lumos Diagnostics Holdings Limited reported revenue of $13.5M in FY2026 versus $11.6M in FY2022, a compound +3.7%/yr. Reported net income was −$5.1M in FY2026.

Key figures

Market cap $66.1M · P/S ratio 5.16 · EPS (TTM) $−0.0100 · Net margin −37.5% · Return on equity −34.1% · Return on assets (EBIT) −38.0% · Operating margin −108% · Revenue (TTM) $13.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 71% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −57%, LDXHF screens richer than that median.

Fair Value models

Bear $0.0200 Fair Value $0.0300 Bull $0.0400

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.0100 $0.0200 $0.0200 53

All 1 models by family

Asset-Based

NCAV (Graham) $0.0100 $0.0200 $0.0200 53

Open the full fair value analysis →

Notify me when LDXHF reaches fair value

Put LDXHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 15/100

Of which business quality 22 · Market factors (momentum, volatility) 20

Profitability 3

Margins and returns on capital today

Quality Growth 29

Are margins and returns improving?

Cashflow 12

Earnings quality: real cash, not paper profit

Fin. Strength 70

Balance sheet, leverage, solvency risk

Investment 6

Disciplined investing over empire-building

Low Volatility 49

Calm price path (market factor)

Momentum 11

Price trend over the last 3–12 months (market factor)

52W Momentum 3

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+7.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−6.6%

Start year 2021 (pandemic)

Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+27.6%

’18

’19

’20

’21

’22

’23

’24

’25

’26

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−58.4% (2021) → −107.1% (2026)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss

not computed

LDXHF screens overvalued: fair value 57% below the price. Compare with Abbott Laboratories, →

Compare Lumos Diagnostics Holdings Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 350 stocks

Beats the industry median on 1/7 measures

Overall it trails its industry peers.

Valuation

Quality Score 22 · Bottom 25%

Profitability

Return on assets −28.7% · Bottom 25%

Net margin (TTM) −37.5% · Bottom 25%

Operating margin (TTM) −107.8% · Bottom 25%

Growth and dividend

Revenue growth 16.0% · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.90× · Pricier than median

P/S (TTM) 5.01× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 10

FUTURE (revenue growth)80 · sector 31

PAST (return on equity)0 · sector 10

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$98.83	$74.79	−24%
Medtronic plc MDT	$87.09	$65.61	−25%
Stryker Corporation SYK	$278.77	$306.65	+10%
Boston Scientific Corporation BSX	$43.65	$48.02	+10%
Edwards Lifesciences Corporation EW	$85.19	$81.94	−4%
Siemens Healthineers AG SHL	€37.86	€35.19	−7%
DexCom, Inc DXCM	$86.68	$95.35	+10%
GE HealthCare Technologies Inc GEHC	$66.63	$70.37	+6%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥153.86	¥169.25	+10%
Koninklijke Philips N.V PHIA	€21.87	€15.23	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lumos Diagnostics Holdings Limited · Fair Value
$0.0300 −57%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/LDXHF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Lumos Diagnostics Holdings Limited · Fair Value</span><br><b style="font-size:20px">$0.0300</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−57%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Lumos Diagnostics Holdings Limited Fair Value". https://www.fairvalue-calculator.com/stock/LDXHF

Frequently asked questions

Is Lumos Diagnostics Holdings Limited (LDXHF) overvalued or undervalued?

As of Jun 24, 2026, our model estimates a fair value of $0.0300 versus a price of $0.0700, about −57% upside (overvalued).

What is the fair value of LDXHF?

Our model-based fair value for Lumos Diagnostics Holdings Limited is $0.0300 (as of Jun 24, 2026), built from audited fundamentals. The current price: $0.0700.

What is the quality score of LDXHF?

Lumos Diagnostics Holdings Limited has a Quality Score of 15/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Lumos Diagnostics Holdings Limited (LDXHF)?

Our model-based price target is the fair value of $0.0300 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario $0.0200, optimistic scenario $0.0400. It is a calculation from audited fundamentals, not an analyst target.

What is the Lumos Diagnostics Holdings Limited stock forecast for 2026?

Our models put fair value at $0.0300, about −57% upside versus a price of $0.0700 (overvalued). Cautious scenario $0.0200, optimistic scenario $0.0400. The calculation is refreshed regularly with new filings.

What is the revenue of Lumos Diagnostics Holdings Limited (LDXHF)?

Lumos Diagnostics Holdings Limited reported trailing-twelve-month revenue of about $13.2M (latest available figure, as of Jun 24, 2026).

What is the intrinsic value of Lumos Diagnostics Holdings Limited (LDXHF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lumos Diagnostics Holdings Limited it is $0.0300 per share (as of Jun 24, 2026), against a price of $0.0700. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Lumos Diagnostics Holdings Limited stock overvalued or undervalued in 2026?

As of Jun 24, 2026, LDXHF trades above its calculated fair value: price $0.0700, fair value $0.0300, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of LDXHF?

No. The price is what the market pays today ($0.0700); the fair value is what the company's own numbers justify ($0.0300). For Lumos Diagnostics Holdings Limited the two are $0.0400 per share apart. That gap is exactly why we show both numbers side by side.

How much is Lumos Diagnostics Holdings Limited worth?

The market values Lumos Diagnostics Holdings Limited at about $66.1M (market capitalisation, as of Jun 24, 2026). Per share that is $0.0700; our models calculate a fair value of $0.0300 per share.

What do the bullish and bearish scenarios say about LDXHF?

Our models span a range for Lumos Diagnostics Holdings Limited: cautious scenario $0.0200, base $0.0300, optimistic $0.0400 per share (as of Jun 24, 2026, price $0.0700). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Lumos Diagnostics Holdings Limited (LDXHF)?

Balance-sheet figures for Lumos Diagnostics Holdings Limited (as of Jun 24, 2026): return on equity −34.1%. They feed the Quality Score of 15/100, which measures business quality independently of the share price.

How far is LDXHF from its 52-week high?

Lumos Diagnostics Holdings Limited trades at $0.0700, about 71% below its 52-week high of $0.2400 and 22% above the low of $0.0576 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0300 is for.

Which stocks are comparable to Lumos Diagnostics Holdings Limited?

From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Lumos Diagnostics Holdings Limited stock attractive at the current price?

The data as of Jun 24, 2026: price $0.0700, calculated fair value $0.0300 (−57%), Quality Score 15/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of LDXHF calculated?

We run Lumos Diagnostics Holdings Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0300, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Lumos Diagnostics Holdings Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Lumos Diagnostics Holdings Limited (LDXHF)?

The closing price on Oct 1, 2026 was $0.0700. Our model-based fair value is $0.0300, about −57% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Lumos Diagnostics Holdings Limited right now?

The price sits above even our optimistic bull case ($0.0400). The favourable scenario is already priced in. Weak quality (15/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0200 to $0.0400) leaves room in how you read the outcome.

Key figures of Lumos Diagnostics Holdings Limited

How large is the market capitalisation of Lumos Diagnostics Holdings Limited (LDXHF)?

The market capitalisation of Lumos Diagnostics Holdings Limited is $66.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Lumos Diagnostics Holdings Limited (LDXHF)?

The price-to-sales ratio of Lumos Diagnostics Holdings Limited is 5.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Lumos Diagnostics Holdings Limited (LDXHF)?

Earnings per share at Lumos Diagnostics Holdings Limited are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Lumos Diagnostics Holdings Limited (LDXHF)?

The net margin of Lumos Diagnostics Holdings Limited is −37.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Lumos Diagnostics Holdings Limited (LDXHF)?

The return on equity (ROE) of Lumos Diagnostics Holdings Limited is −34.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Lumos Diagnostics Holdings Limited (LDXHF)?

On an EBIT basis the return on assets of Lumos Diagnostics Holdings Limited is −38.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Lumos Diagnostics Holdings Limited (LDXHF)?

The operating margin of Lumos Diagnostics Holdings Limited is −108% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Lumos Diagnostics Holdings Limited (LDXHF)?

Revenue at Lumos Diagnostics Holdings Limited is growing +16.0% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Lumos Diagnostics Holdings Limited (LDXHF) generate?

The free cash flow of Lumos Diagnostics Holdings Limited is −$1.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Lumos Diagnostics Holdings Limited (LDXHF) hold?

Lumos Diagnostics Holdings Limited holds more cash than debt, $9.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Lumos Diagnostics Holdings Limited in the live analysis

One click puts Lumos Diagnostics Holdings Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.